R

RAPT Therapeutics
D

RAPT

1.08000
USD
0.04
(3.35%)
Market Closed
Volume
8,367
EPS
-3
Div Yield
-
P/E
-0
Market Cap
37,754,913
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    LLY
    LLY
    -40.34
    (-5.13%)
    748 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    More
News

Title: RAPT Therapeutics

Sector: Healthcare
Industry: Biotechnology
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cellsinto inflamed tissues.